drug
ALVIMOPAN
Marketedupdated 3mo agoby Par Pharmaceutical Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(2)
Trials studying ALVIMOPAN
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 12, 2030
~3.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Feb 12, 2030method-of-use (U-1655)US 89462623.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that